Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Sep 09, 2025

BUY
$27.67 - $42.99 $427,999 - $664,969
15,468 New
15,468 $610 Million
Q1 2025

May 15, 2025

BUY
$27.67 - $42.99 $427,999 - $664,969
15,468 New
15,468 $609,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.5B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Banque Transatlantique Sa Portfolio

Follow Banque Transatlantique Sa and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Banque Transatlantique Sa, based on Form 13F filings with the SEC.

News

Stay updated on Banque Transatlantique Sa with notifications on news.